文献速递肝胆胰外科围术期管理与 ERAS

大范围肝切除术前经动脉治疗与门静脉栓塞的围术期结局全国比较

Transarterial therapies versus portal vein embolization prior to major hepatectomy: A national comparison of perioperative outcomes.
PubMed 文献 · Surgery · 2026-09-03

基于美国外科医师学会国家手术质量改进计划数据库2014至2024年数据,纳入1240例接受右肝切除或三段切除术前门静脉栓塞或经动脉栓塞的患者,比较两种术前肝残端增生方式的围术期结局。经动脉栓塞使用率从2014年8.8%升至2024年23.7%,肝细胞癌患者更可能接受经动脉栓塞,两组输血率、严重肝切除术后肝衰竭及严重并发症发生率相当。

要点

  • 经动脉栓塞术前使用率十年间从8.8%升至2024年23.7%。
  • 肝细胞癌患者接受经动脉栓塞的比值比为4.35。
  • 两组输血、严重肝衰竭及严重并发症率无显著差异。

核心结论

  • 大范围肝切除术前经动脉栓塞使用率过去十年增加,且未伴随相对并发症增加。
  • 在合适临床场景下,经动脉栓塞可作为门静脉栓塞的合理替代方案。

研究设计与样本

  • 回顾性队列研究,查询美国外科医师学会国家手术质量改进计划数据库2014至2024年数据。
  • 纳入接受右肝切除或三段切除术前门静脉栓塞或经动脉栓塞的患者共1240例。
  • 采用单因素和多因素回归分析识别与使用、围术期输血、肝切除术后肝衰竭及严重并发症相关的因素。

主要发现

  • 1240例中1068例(86.1%)接受门静脉栓塞,172例(13.9%)接受经动脉栓塞。
  • 经动脉栓塞使用率从2014年8.8%增至2024年23.7%(P < .001)。
  • 2020年及以后接受切除者更可能接受经动脉栓塞(比值比2.17;95%CI 1.46-3.26;P < .001)。
  • 肝细胞癌患者更可能接受经动脉栓塞(比值比4.35;95%CI 2.41-7.99;P < .001)。
  • 门静脉栓塞组与经动脉栓塞组输血率分别为35.0%(374/1068)与35.5%(61/172),P = .978。

关键数值与推荐

  • 严重肝切除术后肝衰竭率门静脉栓塞组11.2%(120/1068),经动脉栓塞组9.9%(17/172),P = .695。
  • 严重并发症率门静脉栓塞组36.6%(391/1068),经动脉栓塞组34.3%(59/172),P = .618。
  • 校正多因素分析后两组围术期结局无进一步差异。

临床怎么用

  • 在大范围肝切除术前需诱导肝残端增生时,经动脉栓塞可作为门静脉栓塞的替代选择。
  • 肝细胞癌患者及近年手术者更可能接受经动脉栓塞,选择时应结合临床场景。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative liver remnant hypertrophy has historically been achieved with portal vein embolization, but transarterial embolizations, such as radioembolization, have gained interest as alternative hypertrophy mechanisms in select patients. National practice patterns and outcomes between these 2 modalities are poorly characterized. The objective of this study is to compare preoperative utilization of transarterial therapies versus portal vein embolization and assess perioperative outcomes. METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was queried for patients undergoing right hepatectomy or trisegmentectomy after preoperative portal vein embolization or transarterial embolization between 2014 and 2024. Univariable and multivariable regression analyses were performed to identify factors associated with utilization, perioperative transfusion, posthepatectomy liver failure, and serious morbidity. RESULTS: Among 1,240 patients who met inclusion criteria, 1,068 (86.1%) underwent portal vein embolization and 172 (13.9%) underwent transarterial embolization. Transarterial embolization utilization increased from 8.8% in 2014 to 23.7% in 2024 (P < .001). In multivariable analysis, patients were more likely to receive transarterial embolization if they underwent resection in 2020 and after (odds ratio, 2.17; 95% confidence interval, 1.46-3.26; P < .001) or had hepatocellular carcinoma (odds ratio, 4.35; 95% confidence interval, 2.41-7.99; P < .001). Rates of transfusion (374/1,068 [35.0%] vs 61/172 [35.5%], P = .978), serious posthepatectomy liver failure (120/1,068 [11.2%] vs 17/172 [9.9%], P = .695), and serious morbidity (391/1,068 [36.6%] vs 59/172 [34.3%], P = .618) were comparable between portal vein embolization and transarterial embolization, respectively, with no further differences on adjusted multivariable analysis. CONCLUSION: Utilization of transarterial embolization prior to major hepatectomy has increased over the past decade with no associated increase in relative morbidity. In appropriate clinical scenarios, transarterial embolization may serve as a reasonable alternative to portal vein embolization prior to major hepatectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Hughes AJ, Patel DJ, Maatman TK, et al. Transarterial therapies versus portal vein embolization prior to major hepatectomy: A national comparison of perioperative outcomes. Surgery. 2026. PMID: 42838850. doi:10.1016/j.surg.2026.110614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。